Health & Food
Prostate cancer drug rejected by FDA panel
WASHINGTON (KABC) -- A federal panel rejected the use of a new drug for prostate cancer because it could do more harm than good.
The Food and Drug Administration panel said the risk of Merck's Proscar causing patients to develop more aggressive tumors outweighed any benefit it had on low-grade tumors, which are less often fatal.
Studies showed the drug to reduce low-grade tumors by 25 percent, but a small number of men actually developed more aggressive tumors.
GlaxoSmithKline is set to present a similar drug for approval in the near future.
The FDA is not required to follow the recommendations of the panel but usually does.
cancer, men's health, medical research, health & food
- Prostitution bust at OC hotel - exclusive 57 min ago
- MTA bus drivers claim illness from pesticide
- LA plastic-bag ban tentatively approved
- NSA foiled 50+ terrorist plots - director
- Michael Hastings, BuzzFeed reporter, dies 26 min ago
- Torrance man sues over Dorner police shooting
- Cash in paper bag stolen in Altadena robbery
- Zuma Beach bus line launched from Thousand Oaks
- 1,500 evacuated in wildfire near Yosemite
- 7-Eleven stores exploited immigrants - feds
- abcnews: NFL star's home searched after killing
- Zimmerman attorneys pick 40 potential jurors
- Dave Chappelle to headline Funny or Die tour
- OTRC: Lil Wayne talks on American flag controversy
- Latest weather with Dallas Raines
41 min ago